Identifying and Attaining LDL-C Goals: Mission Accomplished? Next Target: New Therapeutic Options to Raise HDL-C Levels

E-ISSN： 1873-5592|8|3|483-488

ISSN： 1389-4501

Source： Current Drug Targets, Vol.8, Iss.3, 2007-01, pp. : 483-488

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The clinical impact of pitavastatin: comparative studies with other statins on LDL-C and HDL-C

By Teramoto Tamio

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 6, 2012-04 ,pp. : 859-865

Informa Healthcare

Access to resources Recommend Favorite

New Drugs for HDL-C Disorders: The Beginning

Current Medicinal Chemistry, Vol. 21, Iss. 25, 2014-08 ,pp. : 2947-2951

Bentham Science Publishers

Access to resources Recommend Favorite

Reduction of Serum LDL-C Levels: A Relationship to Clinical Benefits

By LaRosa J.C.

American Journal of Cardiovascular Drugs, Vol. 3, Iss. 4, 2003-01 ,pp. : 271-281

Adis International

Access to resources Recommend Favorite

Cost of Treating to a Modified European Atherosclerosis Society LDL-C Target: Comparison of Atorvastatin with Fluvastatin, Pravastatin and Simvastatin

By Smith D.G.

Clinical Drug Investigation, Vol. 17, Iss. 3, 1999-03 ,pp. : 185-193

Adis International

Access to resources Recommend Favorite

Micronized Fenofibrate in Dyslipidemia: A Focus on Plasma High-Density Lipoprotein Cholesterol (HDL-C) Levels

By Sharpe M. Ormrod D. Jarvis B.

American Journal of Cardiovascular Drugs, Vol. 2, Iss. 2, 2002-02 ,pp. : 125-132

Adis International

Access to resources Recommend Favorite